AstraZeneca bets $18.5B on next-gen obesity drugs in landmark CSPC deal

AstraZeneca has inked an $18.5 billion deal with CSPC Pharmaceutical Group to enter the thriving stock market of obesity treatment. The partnership grants AstraZeneca access to new drug technologies, including once-a-month dosing options for weight loss. Industry leaders like Mounjaro, Ozempic, and Wegovy currently dominate this fast-growing sector.

Under the agreement, AstraZeneca secures exclusive global rights—outside China—to CSPC's advanced peptide platform. The deal includes an initial $1.2 billion payment, with potential future payments reaching up to $17.3 billion based on development and sales targets.

The collaboration focuses on developing more convenient obesity treatments. CSPC's AI-driven technology enables long-acting and once-a-month formulations, a shift from the daily injections currently on the stock market. AstraZeneca will gain access to eight existing weight loss programs and co-develop four additional drug projects with CSPC.

Sharon Barr, AstraZeneca's executive vice president, called the partnership transformative for the company's weight management portfolio. The deal targets a global obesity market affecting nearly 3 billion people, according to AstraZeneca's estimates.

Dongchen Cai, chairman of CSPC, described the agreement as a 'win-win' for both companies. He highlighted its potential to deliver next-generation treatments for weight management and diabetes. Official announcements and a SEC filing dated January 29–30, 2026, confirmed the partnership's details.

The deal positions AstraZeneca to compete in a market where demand for effective obesity treatments is rising. With CSPC's technology, the company aims to introduce longer-lasting, more patient-friendly options. The partnership also strengthens AstraZeneca's pipeline in diabetes care, expanding its reach beyond existing therapies.